Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia

American Journal of Epidemiology

Volumn 164, Issue 7, 2006, Pages 672-681

  Lambert, Bruce L ^a   Cunningham, Francesca E ^b   Miller, Donald R ^c,d   Dalack, Gregory W ^e,f   Hur, Kwan ^c,g  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Antipsychotic agents; Case control studies; Cohort studies; Diabetes mellitus; Pharmacoepidemiology; Schizophrenia; Veterans

Indexed keywords

HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

COHORT ANALYSIS; DIABETES; DRUG PRESCRIBING; ELDERLY CARE; MENTAL HEALTH; RISK FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; EVALUATION; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES; VETERANS;

NORTH AMERICA; UNITED STATES;

EID: 33749024452     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj289     Document Type: Article

References (77)

1. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:177-9.
2. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci 2001;55:403-14.
3. Beasley CMJ, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1997;16:88-90.
4. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-15.
5. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000967. (Electronic article).
6. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002;36:839-51.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
8. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-26.
9. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
10. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
12. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62:22-31.
13. Meltzer HY, Fleischhacker WW. Weight gain: a growing problem in schizophrenia management. J Clin Psychiatry 2001;62(suppl 7):3.
14. Green AI. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224-35.
15. Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry 2000;61:36-41.
16. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62:41-4.
17. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001;101:277-88.
18. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-81.
19. Melkersson KI, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-8.
20. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-81.
21. Goldstein LE, Henderson DC. Atypical antipsychotic agents and diabetes mellitus. Primary Psychiatry 2000;7:65-8.
22. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
23. Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23: 1037-43.
24. Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71:244-54.
25. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-70.
26. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;111:716-23.
27. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 1999;156:1471.
28. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32.
29. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs - a report of three cases. Diabet Med 2000;17:484-6.
30. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000;20:844-7.
31. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
32. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62:30-8.
33. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16:63-73.
34. Bechara CI, Goldman-Levine JD. Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy 2001;21:1444-7.
35. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001;14:278-82.
36. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001;35:563-5.
37. Roefaro J, Mukherjee SM. Olanzapine-induced hyperglycemic nonketonic coma. Ann Pharmacother 2001;35:300-2.
38. Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000;34:865-7.
39. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. Am J Psychiatry 1999;156:970.
40. Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998;59:687-9.
41. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000;45:668-9.
42. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999;60:556-7.
43. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001;50:148-9.
44. Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoacidosis. Psychosomatics 2001;42:279-80.
45. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000;41:369-70.
46. Mallya A, Chawla P, Boyer SK, et al. Resolution of hyperglycemia on risperidone discontinuation: a case report. J Clin Psychiatry 2002;63:453-4.
47. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.
48. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
49. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58:1172-6.
50. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20.
51. Boyko EJ, Koepsell TD, Gaziano JM, et al. US Department of Veterans Affairs medical care system as a resource to epidemiologists. Am J Epidemiol 2000;151:307-14.
52. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004;27(suppl 2):B10-21.
53. SAS Institute, Inc. SAS OnlineDoc, version 8. Cary, NC: SAS Institute, Inc, 2002. (http://www.okstate.edu/sas/v8/sashtml/main.htm).
54. Allison PD. Survival analysis using the SAS system. Cary, NC: SAS Institute, Inc, 1995.
55. Selvin S. Statistical analysis of epidemiological data. New York, NY: Oxford University Press, 1996.
56. Davies DM, Ferner RE, de Glanville H. Davies's textbook of adverse drug reactions. 5th ed. London, United Kingdom: Arnold Publishers, 1998.
57. Rothman KJ. Modern epidemiology. Boston, MA: Little, Brown and Company, 1986.
58. Stokes M, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC: SAS Institute, Inc, 2000.
59. Rosack J. New studies raise questions about antipsychotic efficacy. Psychiatr News 2003;38:18.
60. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-15.
61. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
62. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
63. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-702.
64. Geddes J. Generating evidence to inform policy and practice: the example of the second-generation "atypical" antipsychotics. Schizophr Bull 2003;29:105-14.
65. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998;49:1081-3.
66. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
67. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26.
68. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63:425-33.
69. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-57.
70. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6.
71. Desai RA, Rosenheck RA, Rothbard A. Cross-system service use among VA mental health patients living in Philadelphia. Adm Policy Ment Health 2001;28:299-309.
72. Hoff RA, Rosenheck RA. Cross-system service use among psychiatric patients: data from the Department of Veterans Affairs. J Behav Health Serv Res 2000;27:98-106.
73. Kane JM, Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull 1985;21:23-7.
74. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Pharmacoeconomics 2000;18:105-24.
75. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
76. Avorn J. Balancing the cost and value of medications: the dilemma facing clinicians. Pharmacoeconomics 2002;20(suppl 3):67-72.
77. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128-35.